Drug Prevents Restenosis in Coronary Syndromes

Abciximab has a modest effect compared with placebo

MONDAY, April 28 (HealthDay News) -- Abciximab modestly prevents restenosis compared with placebo in patients with acute coronary syndromes undergoing percutaneous coronary intervention, researchers report in the May issue of the American Journal of Cardiology.

Raisuke Iijima, M.D., and colleagues from Technische Universitat in Munich, Germany, analyzed the incidence of angiographic in-segment binary restenosis in 1,544 patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention who had been randomly assigned to abciximab or placebo.

The researchers found that the percentage of patients with binary restenosis was lower in the abciximab group but did not reach statistical significance (21.9 versus 24.5 percent). However, the abciximab group had significantly lower percentages of in-stent and in-segment diameter restenoses. Patients in the abciximab group also had a lower one-year incidence of target lesion revascularization, though this did not reach statistical significance (13.6 versus 16.8 percent).

"In conclusion, in patients with non-ST-segment elevation acute coronary syndromes undergoing early percutaneous coronary intervention with stenting after a 600-mg loading dose of clopidogrel, abciximab therapy may have a slight positive impact on the prevention of restenosis," Iijima and colleagues write.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing